1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136: E359‑E386, 2015.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Long‑term outcomes for neoadjuvant versus adjuvant chemo‑ therapy in early breast cancer: Meta‑analysis of individual patient data from ten randomised trials. Lancet Oncol 19: 27‑39, 2018.
3. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, et al: Pathological complete response and long‑term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet 384: 164‑172, 2014.
4. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, et al: Definition and impact of pathologic complete response on prog‑ nosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30: 1796‑1804, 2012.
5. Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway‑Dorsey K, Lenburg ME, et al: Chemotherapy response and recurrence‑free survival in neoad‑ juvant breast cancer depends on biomarker profiles: Results from the I‑SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 132: 1049‑1062, 2012.
6. Foekens JA, Romain S, Look MP, Martin PM and Klijn JG: Thymidine kinase and thymidylate synthase in advanced breast cancer: Response to tamoxifen and chemotherapy. Cancer Res 61: 1421‑1425, 2001.
7. Yu Z, Yang Q, Sun J and Zhen J: Dihydropyrimidine dehydro‑ genase activity correlates with fluorouracil sensitivity in breast cancer. Exp Oncol 29: 192‑196, 2007.
8. Trock BJ, Leonessa F and Clarke R: Multidrug resistance in breast cancer: A meta‑analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 89: 917‑931, 1997.
9. Taheri M and Mahjoubi F: MRP1 but not MDR1 is associated with response to neoadjuvant chemotherapy in breast cancer patients. Dis Markers 34: 387‑393, 2013.
10. Du Y, Zhou Q, Yin W, Zhou L, Di G, Shen Z, Shao Z and Lu J: The role of topoisomerase IIα in predicting sensitivity to anthra‑ cyclines in breast cancer patients: A meta‑analysis of published literatures. Breast Cancer Res Treat 129: 839‑848, 2011.
11. Tokiniwa H, Horiguchi J, Takata D, Kikuchi M, Rokutanda N, Nagaoka R, Sato A, Odawara H, Tozuka K, Oyama T and Takeyoshi I: Topoisomerase II alpha expression and the Ki‑67 labeling index correlate with prognostic factors in estrogen receptor‑positive and human epidermal growth factor type‑2‑negative breast cancer. Breast Cancer 19: 309‑314, 2012.
12. Zhu A, Yuan P, Du F, Hong R, Ding X, Shi X, Fan Y, Wang J, Luo Y, Ma F, et al: SPARC overexpression in primary tumors correlates with disease recurrence and overall survival in patients with triple negative breast cancer. Oncotarget 7: 76628‑76634, 2016.
13. Framson PE and Sage EH: SPARC and tumor growth: Where the seed meets the soil? J Cell Biochem 92: 679‑690, 2004.
14. Brekken RA and Sage EH: SPARC, a matricellular protein: At the crossroads of cell‑matrix communication. Matrix Biol 19: 816‑287, 2001.
15. Arnold SA and Brekken RA: SPARC: A matricellular regulator of tumorigenesis. J Cell Commun Signal 3: 255‑273, 2009.
16. Podhajcer OL, Benedetti LG, Girotti MR, Prada F, Salvatierra E and Llera AS: The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev 27: 691‑705, 2008.
17. Yan Q and Sage EH: SPARC, a matricellular glycoprotein with important biological functions. J Histochem Cytochem 47: 1495‑1506, 1999.
18. Bradshaw AD and Sage EH: SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest 107: 1049‑1054, 2001.
19. Helleman J, Jansen MP, Ruigrok‑Ritstier K, van Staveren IL, Look MP, Meijer‑van Gelder ME, Sieuwerts AM, Klijn JG, Sleijfer S, Foekens JA and Berns EM: Association of an extra‑ cellular matrix gene cluster with breast cancer prognosis and endocrine therapy response. Clin Cancer Res 14: 5555‑5564, 2008.
20. Hsiao YH, Lien HC, Hwa HL, Kuo WH, Chang KJ and Hsieh FJ: SPARC (osteonectin) in breast tumors of different histologic types and its role in the outcome of invasive ductal carcinoma. Breast J 16: 305‑308, 2010.
21. Azim HA Jr, Singhal S, Ignatiadis M, Desmedt C, Fumagalli D, Veys I, Larsimont D, Piccart M, Michiels S and Sotiriou C: Association between SPARC mrna expression, prognosis and response to neoadjuvant chemotherapy in early breast cancer: A pooled in‑silico analysis. PLoS One 8: e62451, 2013.
22. Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A and Bhar P: Significantly longer progression‑free survival with nab‑paclitaxel compared with docetaxel as first‑line therapy for metastatic breast cancer. J Clin Oncol 27: 3611‑3619, 2009.
23. Untch M, Jackisch C, Schneeweiss A, Conrad B, Aktas B, Denkert C, Eidtmann H, Wiebringhaus H, Kümmel S, Hilfrich J, et al: Nab‑paclitaxel versus solvent‑based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto‑GBG 69): A randomised, phase 3 trial. Lancet Oncol 17: 345‑356, 2016.
24. Obayashi S, Horiguchi J, Higuchi T, Katayama A, Handa T, Altan B, Bai T, Bao P, Bao H, Yokobori T, et al: Stathmin1 expression is associated with aggressive phenotypes and cancer stem cell marker expression in breast cancer patients. Int J Oncol 51: 781‑790, 2017.
25. Allred DC, Harvey JM, Berardo M and Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11: 155‑168, 1998.
26. Ledda F, Bravo AI, Adris S, Bover L, Mordoh J and Podhajcer OL: The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J Invest Dermatol 108: 210‑214, 1997.
27. Rempel SA, Golembieski WA, Fisher JL, Maile M and Nakeff A: SPARC modulates cell growth, attachment and migration of U87 glioma cells on brain extracellular matrix proteins. J Neurooncol 53: 149‑160, 2001.
28. Thomas R, True LD, Bassuk JA, Lange PH and Vessella RL: Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res 6: 1140‑1149, 2000.
29. Liu QZ, Gao XH, Chang WJ, Wang HT, Wang H, Cao GW and Fu CG: Secreted protein acidic and rich in cysteine expression in human colorectal cancer predicts postoperative prognosis. Eur Rev Med Pharmacol Sci 19: 1803‑1811, 2015.
30. Guweidhi A, Kleeff J, Adwan H, Giese NA, Wente MN, Giese T, Büchler MW, Berger MR and Friess H: Osteonectin influences growth and invasion of pancreatic cancer cells. Ann Surg 242: 224‑134, 2005.
31. Wang CS, Lin KH, Chen SL, Chan YF and Hsueh S: Overexpression of SPARC gene in human gastric carcinoma and its clinic‑pathologic significance. Br J Cancer 91: 1924‑1930, 2004.
32. Yiu GK, Chan WY, Ng SW, Chan PS, Cheung KK, Berkowitz RS and Mok SC: SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol 159: 609‑622, 2001.
33. Iacobuzio‑Donahue CA, Argani P, Hempen PM, Jones J and Kern SE: The desmoplastic response to infiltrating breast carcinoma: Gene expression at the site of primary invasion and implications for comparisons between tumor types. Cancer Res 62: 5351‑5357, 2002.
34. Nagai MA, Gerhard R, Fregnani JH, Nonogaki S, Rierger RB, Netto MM and Soares FA: Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients. Breast Cancer Res Treat 126: 1‑14, 2011.
35. Schneeweiss A, Seitz J, Smetanay K, Schuetz F, Jaeger D, Bachinger A, Zorn M, Sinn HP and Marmé F: Efficacy of nab‑pacli‑ taxel does not seem to be associated with SPARC expression in metastatic breast cancer. Anticancer Res 34: 6609‑6615, 2014.
36. Lindner JL, Loibl S, Denkert C, Ataseven B, Fasching PA, Pfitzner BM, Gerber B, Gade S, Darb‑Esfahani S, Sinn BV, et al: Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemo‑ therapy. Ann Oncol 26: 95‑100, 2015.
37. Yardley DA: Nab‑Paclitaxel mechanisms of action and delivery. J Control Release 170: 365‑372, 2013.
38. Desai NP, Trieu V, Hwang LY, Wu R, Soon‑Shiong P and Gradishar WJ: Improved effectiveness of nanoparticle albumin‑bound (nab) paclitaxel versus polysorbate‑based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs 19: 899‑909, 2008.
39. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature 406: 747‑752, 2000.
40. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al: Repeated observa‑ tion of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100: 8418‑8423, 2003.
41. Graham JD, Balleine RL, Milliken JS, Bilous AM and Clarke CL: Expression of osteonectin mrna in human breast tumours is inversely correlated with oestrogen receptor content. Eur J Cancer 33: 1654‑1660, 1997.
42. Kurozumi S, Matsumoto H, Hayashi Y, Tozuka K, Inoue K, Horiguchi J, Takeyoshi I, Oyama T and Kurosumi M: Power of PgR expression as a prognostic factor for ER‑positive/HER2‑negative breast cancer patients at intermediate risk classified by the Ki67 labeling index. BMC Cancer 17: 354, 2017.
43. Kurozumi S, Matsumoto H, Inoue K, Tozuka K, Hayashi Y, Kurosumi M, Oyama T, Fujii T, Horiguchi J and Kuwano H: Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer. PLoS One 13: e0201846, 2018.
44. Kurozumi S, Inoue K, Takei H, Matsumoto H, Kurosumi M, Horiguchi J, Takeyoshi I and Oyama T: ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2‑positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab. BMC Cancer 15: 622, 2015.
45. Bekki Y, Yoshizumi T, Shimoda S, Itoh S, Harimoto N, Ikegami T, Kuno A, Narimatsu H, Shirabe K and Maehara Y: Hepatic stellate cells secreting WFA+‑M2BP: Its role in biological interactions with kupffer cells. J Gastroenterol Hepatol 32: 1387‑1393, 2017.
46. Wiese AH, Auer J, Lassmann S, Nährig J, Rosenberg R, Höfler H, Rüger R and Werner M: Identification of gene signatures for invasive colorectal tumor cells. Cancer Detect Prev 31: 282‑195, 2007.
47. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672‑2685, 1998.
48. Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, et al: Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophospha‑ mide for operable breast cancer: National surgical adjuvant breast and bowel project protocol B‑27. J Clin Oncol 24: 2019‑2027, 2006.
49. von Minckwitz G: Neoadjuvant chemotherapy in breast cancer‑insights from the German experience. Breast Cancer 19: 282‑288, 2012.
50. Puolakkainen PA, Brekken RA, Muneer S and Sage EH: Enhanced growth of pancreatic tumors in sparc‑null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. Mol Cancer Res 2: 215‑224, 2004.
51. Said N and Motamed K: Absence of host‑secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carci‑ nomatosis. Am J Pathol 167: 1739‑1752, 2005.
52. Kim H, Samuel S, Lopez‑Casas P, Grizzle W, Hidalgo M, Kovar J, Oelschlager D, Zinn K, Warram J and Buchsbaum D: SPARC‑Independent delivery of nab‑paclitaxel without depleting tumor stroma in patient‑derived pancreatic cancer xenografts. Mol Cancer Ther 15: 680‑688, 2016.